Improving financial incentives for prostate cancer monitoring
Aligning financial incentives to promote rational use of active surveillance for prostate cancer
This study is looking at ways to encourage doctors to choose careful monitoring instead of aggressive treatments for men with low-risk prostate cancer, so they can get paid fairly for keeping an eye on their patients and help them avoid unnecessary side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11105935 on NIH RePORTER |
What this research studies
This research investigates how to align financial incentives to promote the use of active surveillance for men with favorable-risk prostate cancer. It aims to address the financial disincentives that discourage healthcare providers from recommending surveillance over aggressive treatments. By developing alternative payment models, the project seeks to ensure that providers are compensated for monitoring patients rather than pushing for immediate interventions. This approach could lead to better patient outcomes by reducing unnecessary treatments and associated side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with favorable-risk prostate cancer who are currently considering treatment options.
Not a fit: Patients with aggressive forms of prostate cancer or those who require immediate intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more men with prostate cancer receiving appropriate monitoring instead of unnecessary aggressive treatments.
How similar studies have performed: Previous research has shown that aligning financial incentives can improve healthcare delivery, suggesting potential success for this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Shahinian, Vahakn B — University of Michigan at Ann Arbor
- Study coordinator: Shahinian, Vahakn B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.